185750 — Chong Kun Dang Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Market Cap
KR₩1tn
Enterprise Value
KR₩1tn
Revenue
KR₩2tn

Annual income statement for Chong Kun Dang Pharmaceutical, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,343,559	1,488,345	1,669,404	1,586,431	1,692,404
Cost of Revenue
Gross Profit	495,818	542,639	662,202	532,611	526,378
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	1,248,801	1,382,351	1,422,202	1,487,893	1,611,852
Operating Profit	94,759	105,994	247,203	98,538	80,552
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	80,594	97,165	241,598	102,009	81,652
Provision for Income Taxes
Net Income After Taxes	42,356	79,978	213,602	111,442	77,827
Minority Interest
Net Income Before Extraordinary Items
Net Income	42,720	80,953	212,521	109,073	77,509
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	42,720	80,953	212,521	109,073	77,820
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	3,110	6,229	15,861	7,878	5,868
Dividends per Share